Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

RADNOR, Pa. – 2025 年 9 月 17 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, today announced the launch of Libra™, an AI-powered tool for predicting drug-induced liver injury (DILI) to help companies improve safety predictions and optimize R&D portfolios early in drug discovery.

DILI continues to be a major cause of costly late-stage failures and safety concerns. Existing options include investing in costly in vitro studies, waiting to find out in the clinic, or significant investments in simulation tools. Integrated within ToxStudio®, Libra is an intuitive tool that enables researchers to more economically make early data-driven decisions. Libra offers advanced analytics and minimizes reliance on traditional in vivo testing which accords with the FDA’s 2025 roadmap on New Approach Methodologies (NAMs).

“Libra is a major advancement in predictive toxicology,” said Rob Aspbury, President, Certara Predictive Technologies. “With Certara’s expertise, researchers can improve drug safety while accelerating the development process.”

What sets Libra apart:

AI-powered QSAR (Quantitative Structure-Activity Relationship) Modeling: Identifies DILI hazards even before compound synthesis to prioritize safer chemical leads
Bayesian Predictive Model: Integrates physiochemical data and in vitro assay data to flag potential DILI risks early, reducing the number of high-risk compounds advancing unnoticed through the discovery pipeline
易于使用： Intuitive interface accessible to non-modelers
Automated Report Generation: Summarized information and graphics which can also be used in presentations to project teams, governance meetings, and senior management

In addition to Libra, ToxStudio includes:

Secondary Intelligence™: Secondary pharmacology software to contextualize off-target risks
Cardiac Safety Simulator: Modeling and simulation platform designed to predict QT/proarrhythmia risk early

Libra and ToxStudio are part of Certara’s Non-Animal Navigator™ solution which helps sponsors reduce reliance on animal studies in favor of new approach methodologies.

To learn more about Certara’s in silico solutions for toxicology and safety predictions, register for our upcoming webinar and visit https://www.certara.com/toxstudio/.